GSK is stepping up its acquisitions of experimental new drugs in a bid to bolster a pipeline which, although large, has so far failed to inspire investors.
In the past two weeks, Europe's biggest drugmaker has struck three deals potentially worth nearly $4 billion in total, including Tuesday's record-breaking collaboration with Danish firm Genmab for a new leukaemia and arthritis drug.
That deal could earn Genmab as much as $2.1 billion, plus royalties on future sales of HuMax-CD20 that analysts expect to average 20 percent.
More at Reuters
No comments:
Post a Comment